Newsroom

Press Releases


Thermo Fisher Scientific introduces new cell and gene therapy integrated commercial packaging and distribution services

End-to-end solution combines cryogenic and cold chain logistics, serialization compliance and global distribution 



WALTHAM, Mass., February 15, 2022 – Cell and gene therapy innovators can now leverage new integrated commercial packaging and distribution services from Thermo Fisher Scientific, designed to seamlessly transition therapies from clinic to commercial launch for patients across the U.S. and Europe.

 

The Patheon Commercial Packaging Services for Cell and Gene Therapies (CGT) is an end-to-end solution combining the GMP storage, serialization, ultracold and cryogenic packaging, and global distribution that developers need to support their logistics strategies.

 

“There is a large number of cell and gene therapies reaching commercialization in the next few years that will make a significant impact in patients’ lives,” said Chris Armstrong, president, clinical trial services, Thermo Fisher Scientific. “Our integrated services are specifically designed to meet specialized needs for cell and gene therapies to ensure supply chain integrity from manufacturing through packaging, labeling and distribution. This will help accelerate the introduction of these important life-saving medicines.”

 

The cell and gene therapy market is expected to reach a commercialization inflection point, with the FDA anticipating 10-20 new approvals per year through 2025¹. In launching these new therapies, cell and gene therapy developers require specific validated processes for their commercial logistics strategy from labeling to shipping. Highlights of the new services include:

 

  • Regulatory-compliant serialization:   Support for the Drug Supply Chain and Security Act (DSCSA) and Falsified Medicines Directive (FMD) designed to ensure that product identity required for allogeneic products is maintained throughout the supply chain.
  • Deep expertise in commercial cold-chain and cryogenic storage and global distribution: In-house shipper fleet enables seamless distribution, with experience shipping to over 5,000 clinical sites worldwide in over 39 countries. This enables critical therapies to get to the right patient, at the right time, at the right temperature.
  • Patheon Total Transportation Management: White glove courier services for high value shipments provides complete oversight of supply chain.
  • Global infrastructure: Packaging and distribution services available at cryocenters in Frederick, Maryland, and Weil-am-Rhein, Germany, support commercial launches in the U.S. and EU.
  • Clinical to commercial scalability: Experienced project teams with expertise in clinical trials designed to enable commercial success.

 

These new services complement the company’s fully integrated development and manufacturing capabilities for cell and gene therapy, which include translational biology, process development and GMP batch manufacturing services to help streamline the path from discovery to clinic across the entire supply chain. This includes cGMP plasmid manufacturing, viral vector services, and cell therapy manufacturing. These end-to-end solutions, combined with an extensive global supply network, supports cell and gene therapy developers across their project lifecycles and help accelerate access to new life-saving therapies for patients.

 

1. Alliance for Regenerative Medicine. (March 5, 2020). The Alliance for Regenerative Medicine Releases 2019 Annual Report and Sector Year in Review.


About Thermo Fisher Scientific

 

Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue of approximately $40 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics or the development and manufacture of life-changing therapies, we are here to support them. Our global team delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD. For more information, please visit www.thermofisher.com.


Media Contact Information:

 

Erin Morton

Thermo Fisher Scientific

+1 352.554.1441

erin.morton@thermofisher.com

 

Joanne Stanway

Greenough

+1 978.273.1473

jstanway@greenough.biz

 

 

SOURCE Thermo Fisher Scientific

 

If you have any questions regarding this Press Release, please email us at media.relations@thermofisher.com.